Beauty Health (NASDAQ:SKIN) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Beauty Health (NASDAQ:SKIN - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.04, Briefing.com reports. Beauty Health had a negative return on equity of 18.85% and a negative net margin of 25.65%. The firm had revenue of $81.40 million during the quarter, compared to analysts' expectations of $80.56 million. During the same quarter last year, the firm earned ($0.17) earnings per share. The business's revenue for the quarter was down 5.7% on a year-over-year basis. Beauty Health updated its Q2 2024 guidance to EPS.

Beauty Health Stock Down 23.7 %

Beauty Health stock traded down $0.85 during trading on Friday, reaching $2.74. The stock had a trading volume of 6,578,040 shares, compared to its average volume of 1,563,754. Beauty Health has a 52-week low of $1.35 and a 52-week high of $10.98. The business has a 50 day moving average price of $3.70 and a 200 day moving average price of $3.29. The company has a quick ratio of 5.28, a current ratio of 6.07 and a debt-to-equity ratio of 12.43.

Analysts Set New Price Targets

A number of equities research analysts have commented on SKIN shares. TD Cowen lifted their target price on Beauty Health from $2.50 to $4.00 and gave the company a "market perform" rating in a research report on Wednesday, March 13th. Canaccord Genuity Group lifted their price target on shares of Beauty Health from $3.00 to $4.00 and gave the company a "hold" rating in a research report on Thursday, March 14th. Stifel Nicolaus reiterated a "hold" rating and set a $4.00 price target (up from $3.00) on shares of Beauty Health in a research report on Wednesday, March 13th. Piper Sandler dropped their price target on shares of Beauty Health from $3.00 to $2.50 and set an "underweight" rating for the company in a research report on Friday. Finally, DA Davidson reiterated a "buy" rating and set a $5.00 price target on shares of Beauty Health in a research report on Friday, March 15th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat, Beauty Health presently has an average rating of "Hold" and a consensus target price of $6.43.

Beauty Health Company Profile

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.